U.S. BioDefense, Inc.

Letter of Intent filed with U.S. NIH for stem cell research center grant

Published in Managed Care Business Week, March 15th, 2005

U.S. BioDefense, Inc. (UBDE) CEO David Chin announced that the company will file a Letter of Intent (LOI) for grant funding and follow on proposal in response to a request for application (RFA): "Center of Excellence in Translational Human Stem Cell Research" with the U.S. National Institutes of Health (NIH).

NIH components participating organizations include the U.S. National Institute of Neurological Disorders and Stroke (NINDS), U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), U.S. National Heart, Lung, and U.S. Blood Institute (NHLBI).

CEO, David Chin, stated, "The NIH intends to commit up to $4.5 million dollars in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Managed Care Business Week

Source: Managed Care Business Week (2005-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry